These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 31314167)

  • 1. Complementary medicine use and its cost in Australians with type 2 diabetes: the Fremantle Diabetes Study Phase II.
    Yarash T; Sharif I; Masood F; Clifford RM; Davis WA; Davis TME
    Intern Med J; 2020 Aug; 50(8):944-950. PubMed ID: 31314167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of diabetes in Australia: insights from the Fremantle Diabetes Study Phase II.
    Davis WA; Peters KE; Makepeace A; Griffiths S; Bundell C; Grant SFA; Ellard S; Hattersley AT; Paul Chubb SA; Bruce DG; Davis TME
    Intern Med J; 2018 Jul; 48(7):803-809. PubMed ID: 29512259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal Trends in Cardiovascular Complications in People With or Without Type 2 Diabetes: The Fremantle Diabetes Study.
    Davis WA; Gregg EW; Davis TME
    J Clin Endocrinol Metab; 2020 Jul; 105(7):. PubMed ID: 32352534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anemia complicating type 2 diabetes: Prevalence, risk factors and prognosis.
    Gauci R; Hunter M; Bruce DG; Davis WA; Davis TME
    J Diabetes Complications; 2017 Jul; 31(7):1169-1174. PubMed ID: 28433448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of diabetes-attributable non-blood glucose-lowering medication costs in type 2 diabetes: the Fremantle Diabetes Study.
    Davis WA; Knuiman MW; Hendrie D; Davis TM
    Diabetes Care; 2005 Feb; 28(2):329-36. PubMed ID: 15677788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporal Trends in Incident Hospitalization for Diabetes-Related Foot Ulcer in Type 2 Diabetes: The Fremantle Diabetes Study.
    Hamilton EJ; Davis WA; Siru R; Baba M; Norman PE; Davis TME
    Diabetes Care; 2021 Mar; 44(3):722-730. PubMed ID: 33441420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The LEADER trial in type 2 diabetes: Were the characteristics and outcomes of the participants representative?
    Davis TME; Davis WA
    J Diabetes Complications; 2019 Jun; 33(6):427-433. PubMed ID: 31003926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temporal changes in the incidence and predictors of severe hypoglycaemia in type 2 diabetes: The Fremantle Diabetes Study.
    Davis TME; Bruce DG; Finn J; Curtis BH; Barraclough H; Davis WA
    Diabetes Obes Metab; 2019 Mar; 21(3):648-657. PubMed ID: 30370611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence, Incidence and Associates of Pulmonary Hypertension Complicating Type 2 Diabetes: Insights from the Fremantle Diabetes Study Phase 2 and National Echocardiographic Database of Australia.
    Nundlall N; Playford D; Strange G; Davis TME; Davis WA
    J Clin Med; 2021 Sep; 10(19):. PubMed ID: 34640520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and Determinants of Intraocular Lens Implantation in Type 2 Diabetes: The Fremantle Diabetes Study Phase II.
    Drinkwater JJ; Davis TME; Turner AW; Bruce DG; Davis WA
    Diabetes Care; 2019 Feb; 42(2):288-296. PubMed ID: 30523034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-awareness of foot health status in patients with Type 2 diabetes: the Fremantle Diabetes Study Phase II.
    Baba M; Foley L; Davis WA; Davis TM
    Diabet Med; 2014 Nov; 31(11):1439-45. PubMed ID: 24925259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is self-monitoring of blood glucose appropriate for all type 2 diabetic patients? The Fremantle Diabetes Study.
    Davis WA; Bruce DG; Davis TM
    Diabetes Care; 2006 Aug; 29(8):1764-70. PubMed ID: 16873777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporal Trends in Renal Replacement Therapy in Community-Based People with or without Type 2 Diabetes: The Fremantle Diabetes Study.
    Davis WA; Chakera A; Gregg E; McAullay D; Davis TME
    J Clin Med; 2022 Jan; 11(3):. PubMed ID: 35160152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The obesity-driven rising costs of type 2 diabetes in Australia: projections from the Fremantle Diabetes Study.
    Davis WA; Knuiman MW; Hendrie D; Davis TM
    Intern Med J; 2006 Mar; 36(3):155-61. PubMed ID: 16503950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in the Epidemiology of Hepatobiliary Disease Complicating Type 2 Diabetes over 25 Years: The Fremantle Diabetes Study.
    Davis TME; Peters KE; Chubb SAP; Adams LA; Jeffrey GP; Davis WA
    J Clin Med; 2020 Oct; 9(11):. PubMed ID: 33114323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and precipitants of hospitalization for pancreatitis in people with diabetes: the Fremantle Diabetes Study.
    Davis TM; Drinkwater J; Davis WA
    Diabet Med; 2014 Aug; 31(8):913-9. PubMed ID: 24661305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence, characteristics, expenditure and predictors of complementary medicine use in Australians living with gastrointestinal disorders: A cross-sectional study.
    Gan WC; Smith L; McIntyre E; Steel A; Harnett JE
    Complement Ther Clin Pract; 2019 May; 35():158-169. PubMed ID: 31003652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lifetime depression and anxiety increase prevalent psychological symptoms and worsen glycemic control in type 2 diabetes: The Fremantle Diabetes Study Phase II.
    Whitworth SR; Bruce DG; Starkstein SE; Davis WA; Davis TM; Bucks RS
    Diabetes Res Clin Pract; 2016 Dec; 122():190-197. PubMed ID: 27865961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants and costs of community nursing in patients with type 2 diabetes from a community-based observational study: the Fremantle Diabetes Study.
    Davis WA; Lewin G; Davis TM; Bruce DG
    Int J Nurs Stud; 2013 Sep; 50(9):1166-71. PubMed ID: 23245706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.